cancer

Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as…

16 hours ago

Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics

Two leading entities in cancer research pledge scientific collaboration to advance precision oncology.HAMBURG, Germany and ROCHESTER, N.Y., Dec. 10, 2025…

5 days ago

Latest Data of InnoCares Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

December 08, 2025 21:04 ET  | Source: InnoCare Pharma BEIJING, Dec. 08, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969;…

7 days ago

Elekta showcases Evo, its AI-powered, online adaptive CT-Linac at the Association of Medical Physicists of India – National Congress 2025 (AMPICON) in Guwahati

Evo features high-definition image quality and online adaptive radiotherapy capabilities for treating cancerGUWAHATI, India, Dec. 5, 2025 /PRNewswire/ -- Elekta…

1 week ago

Renuka Iyer, MD, Named New Chief Medical Officer for National Comprehensive Cancer Network (NCCN)

Acclaimed oncologist from Roswell Park Comprehensive Cancer Center to help lead nonprofit responsible for gold standard guidelines that define and…

2 weeks ago

Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

AGOURA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today…

2 weeks ago

American Society of Clinical Oncology (ASCO) announces dates for 2026 ASCO Breakthrough and begins accepting submissions for novel oncology research

Global oncology society calls for abstract submissions for research that is shaping the future of cancer care in advance of…

2 weeks ago

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the…

3 weeks ago

Advanced Radiotherapy is a game-changer for India’s cancer care burden

MUMBAI, India, Nov. 27, 2025 /PRNewswire/ -- In a country with over 1.4 million[i] cases reported annually, with most being…

3 weeks ago

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix…

3 weeks ago